Publications by authors named "Muhammed M Er"

Claim this Profile
R
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Seda Kahraman, Enes Erul, Ozge Gumusay, Deniz Can Guven, Sercan Aksoy, Ertugrul Bayram, Hacer Demir, Eda Eylemer Mocan, Alper Yasar, Erkan Kayikcioglu, Omer Acar, Atike Pinar Erdogan, Merve Keskinkilic, Erdem Cubukcu, Cihan Erol, Berna Bozkurt Duman, Sadi Kerem Okutur, Murat Keser, Onder Eren, Muhammed Muhiddin Er, Dincer Aydin, Nazim Serdar Turhal, Serkan Menekse

Clin Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.
Ozkan Alan, Tugba Akın Telli, Sinem Akbas, Selver Isik, Eyyüb Çavdar, Aysegül Merc Cetinkaya, Ferhat Ekinci, Atike Pınar Erdoğan, Muhammed Muhittin Er, Melek Karakurt Eryilmaz, Ertuğrul Bayram, Perran Fulden Yumuk

Medicina (Kaunas)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Ertugrul Bayram, Alper Yasar, Eda Eylemer Mocan, Omer Acar, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Berna Bozkurt Duman, Merve Keskinkilic, Muhammed Muhiddin Er, Nazim Serdar Turhal

BMC Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem

Eur J Clin Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Selver Isik, Adnan Aydiner, Ahmet Taner Sumbul, Serap Akyurek, Merih Yalciner, Muhammed Muhiddin Er, Dincer Aydin, Cihan Erol, Yakup Ergun, Perran Fulden Yumuk

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Muzaffer Uğraklı, Mehmet Zahid Koçak, Gülhan Dinç, Tuğrul Burak Genç, Melek Çağlayan, Muhammed Muhiddin Er, Melek Karakurt Eryılmaz, Çağlayan Geredeli, Orhan Önder Eren

J Cancer Res Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?
Mustafa Korkmaz, Melek Karakurt Eryılmaz, Muhammed Muhiddin Er, Mehmet Zahid Koçak, Aykut Demirkıran

J Gastrointest Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib-induced hepatotoxicity.
Muhammed Muhiddin Er, Murat Araz, Engin Hendem, Melek Karakurt Eryılmaz, Mehmet Artaç

J Oncol Pharm Pract· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Mustafa Korkmaz, Melek K Eryılmaz, Mehmet Z Koçak, Muhammed M Er, Engin Hendem

J Cancer Res Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Omer Acar, Sercan Aksoy, Atike Pinar Erdogan, Alper Yasar, Erkan Kayikcioglu, Merve Keskinkilic, Eda Eylemer Mocan, Onder Eren, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Erdem Cubukcu, Cihan Erol, Sadi Kerem Okutur, Berna Bozkurt Duman, Dincer Aydin, Muhammed Muhiddin Er, Fatih Teker, Murat Keser, Serkan Menekse, Nazim Serdar Turhal

Future Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Serkan Menekşe, Fatih Teker, Nazim Serdar Turhal, Sema Türker, Şener Cihan

Bosn J Basic Med Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor.
Muhammed Muhiddin Er, Murat Araz, Meryem Karabacak, Muzaffer Uğraklı, Melek Karakurt Eryılmaz

J Oncol Pharm Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis